1 / 77

Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)

Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease). Lou Gehrig.

maina
Télécharger la présentation

Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)

  2. Lou Gehrig

  3. ALS is a “motor-neuron” disease, a neurodegenerative disease characterized by the selective death/degeneration of upper motor neurons (in the brain) and lower motor neurons (in the spinal cord). The upper motor neurons normally send the signals to the lower motor neurons, which send signals to muscles.

  4. www.alsa.org

  5. www.alsa.org

  6. A-myo-trophic Lateral Sclerosis Amyotrophic: no muscle nourishment Lateral: refers to the the areas in a person's spinal cord where portions of the nerve cells that signal and control the muscles are located Sclerosis: scarring of the affected nerves

  7. Severe atrophy of anterior spinal roots in motorneuron disease Degeneration of motor neurons in the spinal cord and brainstem results in degeneration of pyramidal tracts and severe atrophy of anterior spinal roots which is demonstrated here.

  8. Atrophic muscle fibers in ALS patients

  9. Muscular atrophy in ALS

  10. Symptoms Earliest signs: 1-twitching (fasciculation), stiffness, cramping 2-weakness of the arms and of the legs. This results in an increased frequency of stumbling on uneven pavement or difficulty in climbing stairs. Arm weakness may lead to difficulty in grasping or holding a cup, for instance, or loss of coordination in fingers 3-more rarely, weakness of the muscles of the mouth. This results in difficulties for the patient to chew, swallow and speak. Later signs: The progression of the disease is accompanied by weight loss, fatigue, exaggerated reflexes, and decreased coordination. Ultimately, patients cannot walk, stand, eat, or breathe without assistance. Increased susceptibility to pneumonia and respiratory failure causes half to die within three years. However, muscles that controls eye movements and urinary sphincters are spared.

  11. Diagnosis of ALS • -No biological marker has been identified yet. • -Series of clinical and neurological exams • -MRI • -myelogram of cervical spine (an x-ray analysis that allows the detection of lesions in selected area of the spinal cord) • muscle and/or nerve biopsy • electromyography (EMG) and nerve conduction velocity (NCV), to measure muscle response to nervous stimulation.

  12. MRI in Amytrophic Lateral Sclerosis (ALS)

  13. Electromyography (EMG) A needle electrode is inserted through the skin into the muscle. Each muscle fiber that contracts will produce an action potential. The presence, size, and shape of the wave form of the action potential produced on the oscilloscope, provides information about the ability of the muscle to respond to nervous stimulation.

  14. Epidemiology of ALS Incidence: 1-2 in 100,000 each year. At the moment in the U.S. there are 25,000 people affected by the disease. Median age of onset is 55 years old. Gender-related incidence: female:male ratio is 4:5. 10% of the cases are inherited, familial cases (FALS), whereas the 90% of the cases are sporadic (SALS) The life-span of a patient affected by ALS is 3 to 5 years, after the diagnosis.

  15. Genetic of ALS

  16. Toxic mechanisms in ALS

  17. Is ALS a mitochondrial disease?

  18. Evidences of mitochondrial dysfunction in SALS: -mitochondria aggregate in skeletal muscle and intramuscular nerve -mitochondria show abnormalities in proximal axons and nerves of the anterior horn of spinal cord -increased mitochondrial volume and calcium level -dysfunction of mitochondrial complex I and IV Decreased ATP production

  19. ALS CONTROL Calcium deposits in mitochondria of ALS patients Syklos et al.,

  20. Evidences that SOD1 could be involved in SALS -Symptoms and pathology of SALS patients are the same as in SOD1 related FALS patients -Pathologic alterations of SOD1 mutant mice are similar to those observed in SALS patients Formation of mitochondrial vacuoles Expansion and rupture of the mitochondrial outer membrane Alterations of calcium homeostasis in the mitochondria Alterations of mitochondrial membrane potential Formation of calcium deposits within the mitochondria

  21. Superoxide Dismutase 1 SOD1 SOD1 is a ubiquitous mostly cytosolic protein SOD1 is comprised of 153 aa with an approximate molecular weight of 16kDa and is an active homodimer Each of the two dimers of SOD1 binds a Cu++ and a Zn++ ion. The reduction of Cu++ to Cu+ is behind the mechanism of SOD1 in regulating the dismutation of superoxide ion O2-.into hydrogen peroxide H2O2 Cu2+ + O2-· Cu+ + O2 Cu+ + O2-· + 2H+ Cu2+ + H2O2 2 O2-· + 2H+ H2O2 + O2 A catalase will subsequently reduce hydrogen peroxide to water.

  22. SOD1 structure: the functional homodimer

  23. Most common mutations in SOD1 related FALS

  24. SOD1 misfolds and aggregates in FALS SOD1A4V motorneurons SEDI Ab SEDI-reactive SOD1 SOD1

  25. Possible roles of mutated SOD1 in FALS Loss of physiological function: impaired dismutase activity Gain of toxic function: 1) Aberrant redox chemistry, probably due to changes in the conformation of SOD1, that leave the channel (the portion of the molecule accepting superoxide ion, i.e.) able to accept larger molecules. This can lead to peroxidation, tyrosine nitrosylation and reverse catalysis (due to improper binding of Zn++ to the molecule that leads to formation of superoxide ion rather than dismutase activity). These activities are not a characteristic of ALL SOD1 mutations, thus remain partially controversial. 2) Protein instability and SOD1 aggregation. These activities are characteristic of all SOD1 mutants.

  26. Models of mutant SOD1-mediated toxicity

  27. O-O…Cu O-O…Cu Zn Zn WT WT Mutant SOD1 may mediate cytotoxic reactions involving:1) Copper catalysis/Zn-mediated toxicity2) Protein aggregation Mutant SOD1 may mediate cytotoxic reactions involving:1) Copper catalysis/Zn-mediated toxicity2) Protein aggregation 4 4 1 1 H H O O Zn Zn Cu Cu H H O O 2 2 3 3 .OH .OH Peroxidation Peroxidation Aggregation Aggregation Cu Cu ONOO ONOO Zn Zn toxic toxic Cu Cu Zn Zn toxic toxic NO-Tyr NO-Tyr Cu, Zn Toxicity Cu, Zn Toxicity Tyrosine Nitration Tyrosine Nitration P.Pasinelli

  28. SOD1 and FALS -More than 125 mutations have been found on the SOD1 gene, 114 are related to ALS, most of them are missense mutations, only 12 are nonsense mutations or deletion mutants. -Most mutations reduce dismutation activity, however others retain full dismutase activity, still are related to the disease. Moreover, there is NO CLEAR CORRELATION between enzyme activity and progression of the disease. -In addition, in animal models, gene KO for SOD1 does not cause motorneuron disease, whereas overexpression of SOD1 does. In this respect, the simple manipulation of SOD1 dismutase activity IS NOT necessarily behind ALS/motorneuron disease.

  29. 1-SOD1 could be modified in SALS 2-SALS and FALS may share the same toxic mechanism of toxicity of SOD1

  30. Can SOD1 form aggregates also in SALS?

  31. wtSOD1 can be oxidized

  32. SOD1 conformation-specific antibody

  33. Conformation-specific SOD1 antibody detects oxSOD1 in non-denaturing conditions…

  34. …but not in denaturing conditions: SOD1 oxidation as a mechanism to form SOD1 aggregates

  35. SOD1 oxidation inhibits anterograde Fast Axonal Transport FAT

  36. oxSOD1 affects the activity of p38MAPK, a protein that regulates FAT

  37. Inhibition of p38MAPK reverts the effects of oxSOD1 on FAT

  38. Sequestration of conformation-specific oxSOD1 reverts the effects of wtSOD1 on FAT in SALS

  39. Conformation-specific SOD1 antibody reacts with wtSOD1 only in SALS

  40. How SOD1 aggregates could be toxic? 1- Formation of small and large aggregates that may impairs proteasomal activity. This would result in lack of proper degradation of different proteins including toxic mutant SOD1. 2- Sequestration within the aggregate of proteins that are important for the cell, like heat shock proteins (HSP70), thus impairing the physiological “protective” activity of these proteins. 3-SOD1 can sequester into aggregates the anti-apoptotic Bcl2. 4- Formation of SOD1 aggregates can be related to mitochondrial dysfunction and apoptosis.

  41. SOD1 aggregates: mitochondrial dysfunction and apoptosis

  42. 1- Cluster of abnormal mitochondria and morphological defect (in muscles cells and in motorneuron) Complex I and IV are defective, paralleled by increased mitochondrial Ca++ levels. 2-in vitro and in vivo, SOD1 mutants *cause depolarization of mitochondria *decrease levels of ATP 3- Vacuolated mitochondria: detachment between the outer and the inner membrane, crystae disruption. Is mitochondrial dysfunction a cause or a consequence?

  43. How could mutant SOD1 be related to mitochondrial defects? Altering mitochondrial structure, causing formation of vacuoles and ultimately rupture of the mitochondrial outer membrane leading to apoptosis

  44. SOD1 associates to Bcl2, but not to Bax, in vitro… Exogenous SOD1 Endogenous SOD1

  45. …and in vivo mice Human spinal cord

  46. Bcl2 binds aggregated SOD1 in animal models of ALS…

  47. …and in spinal cord of ALS patients FALS SOD1 A4V

  48. Mutant SOD1 binds Bcl2 specifically in the mitochondria

  49. SOD1 aggregates recruit Bcl2 and start apoptosis in FALS

More Related